{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T01:38:12Z","timestamp":1721180292485},"reference-count":122,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2007,9,1]],"date-time":"2007-09-01T00:00:00Z","timestamp":1188604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2007,9]]},"DOI":"10.1016\/j.canlet.2007.02.009","type":"journal-article","created":{"date-parts":[[2007,3,24]],"date-time":"2007-03-24T07:06:08Z","timestamp":1174719968000},"page":"12-25","source":"Crossref","is-referenced-by-count":15,"title":["Cytogenetic and molecular aspects of Philadelphia negative chronic myeloproliferative disorders: Clinical implications"],"prefix":"10.1016","volume":"255","author":[{"given":"Anna D.","family":"Panani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2007.02.009_bib1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2007.02.009_bib2","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0950-3536(98)80035-8","article-title":"Diagnosis and classification of erythrocytosis and thrombocytosis","volume":"11","author":"Pearson","year":"1998","journal-title":"Baillieres Clin. Haematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib3","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1053\/beha.2001.0153","article-title":"Myeloproliferative disorders","volume":"14","author":"Bench","year":"2001","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib4","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0950-3536(98)80041-3","article-title":"Molecular genetics and cytogenetics of myeloproliferative disorders","volume":"11","author":"Bench","year":"1998","journal-title":"Baillieres Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib5","doi-asserted-by":"crossref","first-page":"174","DOI":"10.4065\/78.2.174","article-title":"Polycythemia vera: a comprehensive review and clinical recommendations","volume":"78","author":"Tefferi","year":"2003","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.canlet.2007.02.009_bib6","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00277-002-0604-y","article-title":"Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients","volume":"82","author":"Thiele","year":"2003","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib7","first-page":"9","article-title":"Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia","volume":"36","author":"Murphy","year":"1999","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib8","first-page":"29","article-title":"Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival and leukemia transition by treatment","volume":"34","author":"Murphy","year":"1997","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib9","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1046\/j.1365-2141.2001.03168.x","article-title":"Idiopathic erythocytosis: a declining entity","volume":"115","author":"Blacklock","year":"2001","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib10","first-page":"6","article-title":"The very long-term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981","volume":"34","author":"Najean","year":"1997","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib11","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1182\/blood-2001-12-0349","article-title":"Polycythemia vera: myths, mechanisms and management","volume":"100","author":"Spivak","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2007.02.009_bib12","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/j.seminhematol.2005.08.001","article-title":"Chromosomal abnormalities and molecular markers in myeloproliferative disorders","volume":"42","author":"Bench","year":"2005","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/01.moh.0000208469.48614.2e","article-title":"New insights into the pathogenesis and drug treatment of myelofibrosis","volume":"13","author":"Tefferi","year":"2006","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.beha.2005.07.001","article-title":"Classification of chronic myeloid disorders: from Dameshec towards a semi-molecular system","volume":"19","author":"Tefferi","year":"2006","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib15","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.beha.2005.07.014","article-title":"Classic and atypical myeloproliferative disorders","volume":"19","author":"Tefferi","year":"2006","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib16","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.leukres.2005.11.011","article-title":"FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy and a critical review of the literature","volume":"30","author":"Pardanani","year":"2006","journal-title":"Leuk. Res."},{"key":"10.1016\/j.canlet.2007.02.009_bib17","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.semcancer.2003.11.004","article-title":"Targeted treatment of hypereosinophilic syndrome and chronic eosinophilic leukemias with imatinib mesylate","volume":"14","author":"Coutre","year":"2004","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.canlet.2007.02.009_bib18","doi-asserted-by":"crossref","first-page":"22788","DOI":"10.1074\/jbc.C500138200","article-title":"Identification of an acquired JAK2 mutation in polycythemia vera","volume":"280","author":"Zhao","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2007.02.009_bib19","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2007.02.009_bib20","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2007.02.009_bib21","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2007.02.009_bib22","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain of function mutation in JAK2 is frequently found in patients with myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2007.02.009_bib23","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2007.02.009_bib24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1634\/stemcells.2004-0117","article-title":"Normal and oncogenic forms of the receptor tyrosine kinase kit","volume":"23","author":"Lennartsson","year":"2005","journal-title":"Stem Cells"},{"key":"10.1016\/j.canlet.2007.02.009_bib25","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1002\/ajmg.10689","article-title":"Molecular cytogenetic aspects of hematological malignancies: clinical implications","volume":"115","author":"Chen","year":"2002","journal-title":"Am. J. Med. Genet. (Semin. Med. Genet.)"},{"key":"10.1016\/j.canlet.2007.02.009_bib26","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0025-6196(12)61011-8","article-title":"Chromosome studies in 104 patients with polycythemia vera","volume":"68","author":"Diez Martin","year":"1991","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.canlet.2007.02.009_bib27","first-page":"464","article-title":"Polycythemia vera: analysis of DNA from blood granulocytes using comparative genomic hybridization","volume":"86","author":"Westwood","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.canlet.2007.02.009_bib28","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1046\/j.1365-2141.2000.02242.x","article-title":"The incidence of trisomy 8, trisomy 9 and D20S108 deletion in polycythemia vera: an analysis of blood granulocytes using interphase fluorescence in situ hybridization","volume":"110","author":"Westwood","year":"2000","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib29","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1046\/j.1365-2141.2002.03763.x","article-title":"Exploring polycythemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected","volume":"119","author":"Najfeld","year":"2002","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib30","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cancergencyto.2003.09.011","article-title":"Is fluorescence in situ hybridization a useful method in diagnosis of polycythemia vera patients?","volume":"151","author":"Zamora","year":"2004","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.canlet.2007.02.009_bib31","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1038\/sj.leu.2402980","article-title":"Molecular cytogenetics of polycythemia vera: lack of occult rearrangements detectable by 20q LSP screening","volume":"17","author":"Gribble","year":"2003","journal-title":"CGH and M-FISH, Leuk."},{"key":"10.1016\/j.canlet.2007.02.009_bib32","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/(SICI)1098-2264(199808)22:4<321::AID-GCC8>3.0.CO;2-X","article-title":"Gain of 9p in the pathogenesis of polycythemia vera","volume":"22","author":"Chen","year":"1998","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.canlet.2007.02.009_bib33","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1182\/blood-2003-03-0744","article-title":"Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders","volume":"102","author":"Kralovics","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2007.02.009_bib34","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0301-472X(01)00789-5","article-title":"Aquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera","volume":"30","author":"Kralovics","year":"2002","journal-title":"Exp. Hematol."},{"issue":"Suppl. I","key":"10.1016\/j.canlet.2007.02.009_bib35","first-page":"497","article-title":"Interphase FISH (I-FISH) in polycythemia vera (PV): a new tool for diagnosis and for providing insights into the biology of abnormal clones","volume":"94","author":"Montella","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2007.02.009_bib36","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1046\/j.1365-2141.2001.02796.x","article-title":"Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia","volume":"113","author":"Tefferi","year":"2001","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib37","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1046\/j.1365-2141.1997.1722990.x","article-title":"Cytogenetic abnormalities and their prognostic significance in idiopathic myelofibrosis: a study of 106 cases","volume":"98","author":"Reilly","year":"1997","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib38","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","article-title":"Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system","volume":"88","author":"Dupriez","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2007.02.009_bib39","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1002\/cncr.21358","article-title":"Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia","volume":"104","author":"Tefferi","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2007.02.009_bib40","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1002\/cncr.22318","article-title":"Prognostic relevance of cytogenetics determined by fluorescent in situ hybridization in patients having myelofibrosis with myeloid metaplasia","volume":"107","author":"Strasser-Weippl","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2007.02.009_bib41","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","article-title":"Leukemic transformation in myelofibrosis with myeloid metaplasia:a single institution experience with 91 cases","volume":"105","author":"Mesa","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2007.02.009_bib42","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1182\/blood-2004-11-4319","article-title":"Chromosome 7 deletions are associated with unfavorable prognosis in myelofibrosis with myeloid metaplasia","volume":"105","author":"Strasser-Weippl","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2007.02.009_bib43","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/cncr.21868","article-title":"Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis","volume":"106","author":"Dingli","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2007.02.009_bib44","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/S0165-4608(02)00678-7","article-title":"Karyotypic abnormalities in myelofibrosis following polycythemia vera","volume":"140","author":"Andrieux","year":"2003","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.canlet.2007.02.009_bib45","first-page":"381","article-title":"Cytogenetic findings in untreated patients with essential thrombocythemia","volume":"20","author":"Panani","year":"2006","journal-title":"In Vivo"},{"key":"10.1016\/j.canlet.2007.02.009_bib46","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0165-4608(00)00389-7","article-title":"No increased frequency of trisomies 8 and 9 by fluorescence in situ hybridization in untreated patients with essential thrombocythemia","volume":"126","author":"Swolin","year":"2001","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.canlet.2007.02.009_bib47","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0165-4608(01)00410-1","article-title":"Comparative genomic hybridization in polycythemia vera and essential thrombocytosis patients","volume":"128","author":"Herishanu","year":"2001","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.canlet.2007.02.009_bib48","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1034\/j.1600-0609.2002.01601.x","article-title":"Leukemic transformation with trisomy 8 in essential thrombocythemia","volume":"68","author":"Hirose","year":"2002","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib49","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0165-4608(03)00215-2","article-title":"A novel t(2;17) in transformation of essential thrombocythemia to acute myeloid leukemia","volume":"148","author":"Lazarevic","year":"2004","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.canlet.2007.02.009_bib50","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s00277-004-0977-1","article-title":"Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information","volume":"84","author":"Bacher","year":"2005","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib51","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/ajcp\/106.5.680","article-title":"Hematologic disorders associated with deletions of chromosome 20q: a clinicopathologic study of 107 patients","volume":"106","author":"Kurtin","year":"1996","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.canlet.2007.02.009_bib52","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1182\/blood.V84.9.3086.3086","article-title":"Molecular analysis of chromosome 20q deletions associated with myeloproliferative disorders and myelodysplastic syndromes","volume":"84","author":"Asimakopoulos","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2007.02.009_bib53","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0165-4608(94)00150-A","article-title":"Characterization of 20q deletions in patients with myeloproliferative disorders or myelodysplastic syndromes","volume":"80","author":"Nacheva","year":"1995","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.canlet.2007.02.009_bib54","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1038\/sj.onc.1203728","article-title":"Chromosome 20 deletions in myeloid malignancies: reduction of the common deleted region, generation of a PAC\/BAC contig and identification of candidate genes","volume":"19","author":"Bench","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2007.02.009_bib55","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/(SICI)1098-2264(199802)21:2<75::AID-GCC1>3.0.CO;2-4","article-title":"Refinement of the commonly deleted segment in myeloid leukemias with a del(20q)","volume":"21","author":"Wang","year":"1998","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.canlet.2007.02.009_bib56","doi-asserted-by":"crossref","first-page":"15412","DOI":"10.1074\/jbc.M300592200","article-title":"The human L3MBT polycomb group protein is a transcriptional repressor and interacts physically and functionally with TEL(ETV6)","volume":"278","author":"Boccuni","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.canlet.2007.02.009_bib57","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1365-2141.2004.05278.x","article-title":"Characterization of the imprinted polycomb gene L3MBTL a candidate 20q tumor suppressor gene, in patients with myeloid malignancies","volume":"127","author":"Bench","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib58","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/gcc.20087","article-title":"Structural integrity and expression of the L3MBTL gene in normal and malignant hematopoietic cells","volume":"41","author":"MacGrogan","year":"2004","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.canlet.2007.02.009_bib59","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.canlet.2005.04.011","article-title":"Cytogenetic aspects of adult primary myelodysplastic syndromes: clinical implications","volume":"235","author":"Panani","year":"2006","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2007.02.009_bib60","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0165-4608(92)90043-8","article-title":"Clinical significance of the del(20q) chromosome in hematologic disorders","volume":"62","author":"Aatola","year":"1992","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.canlet.2007.02.009_bib61","first-page":"67","article-title":"The prognostic significance of deletion of the long arm of chromosome 20 in myeloid disorders","volume":"8","author":"Campbell","year":"1994","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2007.02.009_bib62","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.cancergencyto.2004.12.019","article-title":"Prognostic significance of del(20q) in patients with hematological malignancies","volume":"160","author":"Brezinova","year":"2005","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.canlet.2007.02.009_bib63","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/(SICI)1097-0142(20000315)88:6<1359::AID-CNCR12>3.0.CO;2-Q","article-title":"Deletions in the 13q14 locus in adult lymphoblastic leukemia: rate of incidence and relevance","volume":"88","author":"Chung","year":"2000","journal-title":"Cancer"},{"issue":"Suppl. I","key":"10.1016\/j.canlet.2007.02.009_bib64","first-page":"4062","article-title":"An analysis of chromosome 13q14 deletions in myelofibrosis using FISH and Southern-based hybridization","volume":"90","author":"Gardiner","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2007.02.009_bib65","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1002\/gcc.2870140204","article-title":"Genetic analysis of chromosome 13 deletions in BCR\/ABL negative chronic myeloproliferative disorders","volume":"14","author":"Pastore","year":"1995","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.canlet.2007.02.009_bib66","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2141.2005.05413.x","article-title":"Gains on 9p are common genomic aberrations in idiopathic myelofibrosis: a comparative genomic hybridization study","volume":"129","author":"Al-Assar","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib67","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1182\/blood.V95.6.1925","article-title":"Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization","volume":"95","author":"Zojer","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2007.02.009_bib68","first-page":"1059","article-title":"Extra translocation +der(1q9p) is a prognostic indicator in myeloproliferative disorders","volume":"5","author":"Rege Cambrin","year":"1991","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2007.02.009_bib69","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/gcc.10297","article-title":"Dysregulation and overexpression of HMGA2 in myelofibrosis with myeloid metaplasia","volume":"39","author":"Andrieux","year":"2004","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.canlet.2007.02.009_bib70","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000046639","article-title":"The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1","volume":"107","author":"Macdonald","year":"2002","journal-title":"Acta Haematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib71","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/sj.onc.1201601","article-title":"t(8;9) and t(8;13) translocations associated with stem cell myeloproliferative disorders have close or identical breakpoints in chromosome region 8p11\u201312","volume":"16","author":"Chaffanet","year":"1998","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2007.02.009_bib72","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/gcc.1177","article-title":"Identification of four new translocations involving FGFR1 in myeloid disorders","volume":"32","author":"Sohal","year":"2001","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.canlet.2007.02.009_bib73","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/ng0198-84","article-title":"FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukemia\/lymphoma syndrome","volume":"18","author":"Xiao","year":"1998","journal-title":"Nat. Genet."},{"key":"10.1016\/j.canlet.2007.02.009_bib74","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1182\/blood.V93.4.1381","article-title":"The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1","volume":"93","author":"Popovici","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2007.02.009_bib75","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1182\/blood.V96.2.699","article-title":"ZNF198-FGFR1 transforming activity depends on a novel proline-rich ZNF198 oligomerization domain","volume":"96","author":"Xiao","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2007.02.009_bib76","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1182\/blood.V85.7.1881.bloodjournal8571881","article-title":"A syndrome of lymphoblastic lymphoma, eosinophilia and myeloid hyperplasia\/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity","volume":"85","author":"Inhorn","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2007.02.009_bib77","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000046641","article-title":"Myeloproliferative disorders with translocations 5q31\u201335: role of the platelet-derived growth factor receptor beta","volume":"107","author":"Steer","year":"2002","journal-title":"Acta Haematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib78","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1046\/j.1365-2141.2003.04051.x","article-title":"Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFR\u03b2) gene in BCR\/ABL negative chronic myeloproliferative disorders","volume":"120","author":"Baxter","year":"2003","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib79","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0092-8674(94)90322-0","article-title":"Fusion of PDGF receptor \u03b2 to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation","volume":"77","author":"Colub","year":"1994","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2007.02.009_bib80","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1001\/archderm.140.5.584","article-title":"Unexplained hypereosinophilia and the need for cytogenetic and molecular genetics analyses","volume":"140","author":"Smith","year":"2004","journal-title":"Arch. Dermatol."},{"key":"10.1016\/j.canlet.2007.02.009_bib81","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2007.02.009_bib82","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1182\/blood-2003-06-1824","article-title":"The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification and management","volume":"103","author":"Gotlib","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2007.02.009_bib83","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.beha.2005.07.013","article-title":"Eosinophilic disorders: molecular pathogenesis, new classification and modern therapy","volume":"19","author":"Gotlib","year":"2006","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib84","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cancergencyto.2005.02.021","article-title":"Leukemic recombinations involving heterochromatin in myeloproliferative disorders with t(1;9)","volume":"162","author":"Sambani","year":"2005","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.canlet.2007.02.009_bib85","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cancergencyto.2004.12.015","article-title":"Gain of 9p due to an unbalanced rearrangement der (9;18): a recurrent clonal abnormality in chronic myeloproliferative disorders","volume":"160","author":"Bacher","year":"2005","journal-title":"Cancer Genet. Cytogenet."},{"key":"10.1016\/j.canlet.2007.02.009_bib86","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/1024533031000107488","article-title":"Molecular markers in myeloproliferative disorders: from classification to prognosis?","volume":"8","author":"Pahl","year":"2003","journal-title":"Hematology"},{"key":"10.1016\/j.canlet.2007.02.009_bib87","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.patbio.2003.09.019","article-title":"Molecular markers for the diagnosis of Philadelphia chromosome negative myeloproliferative disorders","volume":"52","author":"Klippel","year":"2004","journal-title":"Pathol. Biol."},{"key":"10.1016\/j.canlet.2007.02.009_bib88","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0037-1963(01)90135-0","article-title":"Pathogenetic mechanisms of polycythemia vera and congenital polycythemic disorders","volume":"38","author":"Prchal","year":"2001","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib89","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3109\/10428199609074366","article-title":"Diagnostic application of hemopoietic progenitor culture techniques in polycythemias and thrombocythemias","volume":"22","author":"Westwood","year":"1996","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.canlet.2007.02.009_bib90","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1056\/NEJM199802263380903","article-title":"Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera","volume":"338","author":"Moliterno","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2007.02.009_bib91","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1182\/blood-2003-03-0919","article-title":"Quantification of PRV-1 mRNA distinguishes polycythemia vera from secondary erythrocytosis","volume":"102","author":"Klippel","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2007.02.009_bib92","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1182\/blood-2003-10-3505","article-title":"Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia","volume":"103","author":"Tefferi","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2007.02.009_bib93","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood.V95.8.2569","article-title":"Cloning of PRV-1, a novel member of the Upar receptor superfamily, which is overexpressed in polycythemia rubra vera","volume":"95","author":"Temerinac","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2007.02.009_bib94","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-2141.2005.05416.x","article-title":"Gene expression profiling in polycythemia vera: overexpression of transcription factor NF-E2","volume":"129","author":"Goerttler","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib95","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.beha.2005.07.003","article-title":"Polycythemia vera and molecular basis: an update","volume":"19","author":"Chen","year":"2006","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib96","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2141.2006.06206.x","article-title":"The role of Janus kinases in haemopoiesis and haematological malignancy","volume":"134","author":"Khwaja","year":"2006","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib97","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","article-title":"Expression of JAK2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model","volume":"107","author":"Wernig","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2007.02.009_bib98","doi-asserted-by":"crossref","first-page":"11156","DOI":"10.1158\/0008-5472.CAN-06-2210","article-title":"Characterization of murine JAKV617F positive myeloproliferative disease","volume":"66","author":"Bumm","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2007.02.009_bib99","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/ajh.20721","article-title":"Identification of JAK2 V617F in patients with polycythemia is highly correlated with conventional criteria for diagnosis of polycythemia vera","volume":"82","author":"Ganly","year":"2007","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib100","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.leukres.2006.02.027","article-title":"Usefulness of JAK2 V617F mutation in distinguishing idiopathic erythrocytosis from polycythemia vera","volume":"31","author":"Rossi","year":"2007","journal-title":"Leuk. Res."},{"key":"10.1016\/j.canlet.2007.02.009_bib101","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2007.02.009_bib102","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","article-title":"The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both atypical myeloproliferative disorders and myelodysplastic syndromes","volume":"106","author":"Steensma","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2007.02.009_bib103","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1182\/blood-2005-05-1898","article-title":"The JAK2 V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia","volume":"106","author":"Levine","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2007.02.009_bib104","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood-2005-05-1800","article-title":"JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML and megakaryocytic leukemia","volume":"106","author":"Jelinek","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2007.02.009_bib105","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/sj.leu.2403903","article-title":"JAK2 Val617Phe activating tyrosine kinase mutation in juvenile myelomonocytic leukemia","volume":"19","author":"Tono","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2007.02.009_bib106","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2005-05-2087","article-title":"The JAK2 V617F mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders","volume":"106","author":"Scott","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2007.02.009_bib107","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1365-2141.2005.05697.x","article-title":"The V617F mutation in JAK2 is not found in childhood acute lymphoblastic leukemia","volume":"130","author":"Sulong","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib108","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/j.1365-2141.2005.05719.x","article-title":"JAK2 V617F mutation is uncommon in chronic myelomonocytic leukemia","volume":"130","author":"Johan","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib109","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/10428190500301348","article-title":"JAK2 V617F in myeloid disorders: what do we know now, and where are we headed?","volume":"47","author":"Nelson","year":"2006","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.canlet.2007.02.009_bib110","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1365-2141.2005.05743.x","article-title":"Concominant neutrophil JAK2 V617F mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythemia","volume":"131","author":"Tefferi","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib111","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1182\/blood-2005-05-1889","article-title":"Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of JAK2","volume":"106","author":"Kralovics","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2007.02.009_bib112","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/cncr.21787","article-title":"Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2V617F and response to erythropoietin therapy","volume":"106","author":"Tefferi","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2007.02.009_bib113","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.leukres.2006.01.008","article-title":"JAK2 V617F and leukemic transformation in myelofibrosis with myeloid metaplasia","volume":"30","author":"Mesa","year":"2006","journal-title":"Leuk. Res."},{"key":"10.1016\/j.canlet.2007.02.009_bib114","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1365-2141.2006.06288.x","article-title":"JAK2 V617F mutation in leukemic transformation of Philadelphia negative chronic myeloproliferative disorders","volume":"135","author":"Rossi","year":"2006","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib115","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.21645","article-title":"The clinical phenotype of wild-type, heterozygous and homozygous JAK2V617F in polycythemia vera","volume":"106","author":"Tefferi","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2007.02.009_bib116","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1365-2141.2006.06174.x","article-title":"Hemizygous\/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour","volume":"134","author":"Ma","year":"2006","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib117","doi-asserted-by":"crossref","unstructured":"M. Speletas, E. Katodritou, C. Daiou, E. Mandala, E. Papadakis, A. Kioumi, K. Ritis, I. Korantzis, Correlation of JAK2 V617F mutation with clinical and laboratory findings in patients with myeloproliferative disorders, Leuk. Res. available on line September 2006.","DOI":"10.1016\/j.leukres.2006.09.005"},{"key":"10.1016\/j.canlet.2007.02.009_bib118","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-2141.2005.05776.x","article-title":"The JAK2 V617F tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates","volume":"131","author":"Tefferi","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib119","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythemia and relation to polycythemia vera based on JAK2 V617F mutation status: a prospective study","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2007.02.009_bib120","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1600-0609.2006.00688.x","article-title":"JAK2 V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphprylation status","volume":"77","author":"Heller","year":"2006","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib121","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2005.05858.x","article-title":"The presence of JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythemia","volume":"132","author":"Cheung","year":"2005","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canlet.2007.02.009_bib122","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","article-title":"JAK2 V617F mutation in essential thrombocythemia: clinical associations and long-term prognostic relevance","volume":"131","author":"Wolanskyj","year":"2005","journal-title":"Br. J. Haematol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383507000663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383507000663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,20]],"date-time":"2020-04-20T22:16:48Z","timestamp":1587421008000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383507000663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,9]]},"references-count":122,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["S0304383507000663"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2007.02.009","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2007,9]]}}}